Giulia Gardini

Dr. Giulia Gardini

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
LPLaura Pini
Laura Pini
JGJordan Giordani
Jordan Giordani
GGGiulia Gardini
Giulia Gardini
CCCarlo Concoreggi
Carlo Concoreggi
APAlessandro Pini
Alessandro Pini
CTClaudio Tantucci
Claudio Tantucci

4 June 2021 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
IIIlaria Izzo
Ilaria Izzo
CCCanio Carriero
Canio Carriero
GGGiulia Gardini
Giulia Gardini
BFBenedetta Fumarola
Benedetta Fumarola
ECErika Chiari
Erika Chiari
EReugenia quiros roldan
eugenia quiros roldan
Background: Brescia Province, northern Italy, was one of the worst epicenters of the COVID-19 pandemic. The division of infectious diseases of ASST (Azienda Socio Sanitaria Territoriale) Spedali Civili Hospital of Brescia had to face a great number of inpatients with severe COVID-19 infection and to ensure the continuum of care for almost 4000 outpatients with HIV infection actively followed by us. In a recent manuscript we described the impact of the pandemic on continuum of care in our HIV cohort expressed as number of missed visits, number of new HIV diagnosis, drop in ART (antiretroviral therapy) dispensation and number of hospitalized HIV patients due to SARS-CoV-2 infection. In this short communication, we completed the previous article with data of HIV plasmatic viremia of the same cohort before and during pandemic. Methods: We considered all HIV-patients in stable ART for at least 6 months and with at least 1 available HIV viremia in the time window March 01–November 30, 2019, and another group of HIV patients with the same two requisites but in different time windows of the COVID-19 period (March 01–May 31, 2020, and June 01–November 30, 2020). For patients with positive viremia (PV) during COVID-19 period, we reported also the values of viral load (VL) just before and after PV. Results: the percentage of patients with PV during COVID-19 period was lower than the previous year (2.8% vs 7%). Only 1% of our outpatients surely suffered from pandemic in term of loss of previous viral suppression. Conclusions: Our efforts to limit the impact of pandemic on our HIV outpatients were effective to ensure HIV continuum of care.

31 January 2022 in Journal of Public Health Research
Verified
Journal Article
Open access
PDF file
EReugenia quiros roldan
eugenia quiros roldan
IIIlaria Izzo
Ilaria Izzo
CCCanio Carriero
Canio Carriero
MAMelania Degli Antoni
Melania Degli Antoni
SSSamuele Storti
Samuele Storti
Francesco CastelliFrancesco Castelli
Francesco Castelli
The emergence SARS-CoV-2 in late 2019 and early 2020 has caused a pandemic of unprecedented proportions. Management of COVID-19 became emergent public health priorities, and the impact on other public health initiatives, such as expanded HIV screening and linkage to care, remain largely unknown. In this Single-Center retrospective observational study, we describe the characteristics and circumstance of the new HIV cases during 2020 compared to 2019. We observed a decrease of HIV diagnosis during this period. Interestingly, median age at HIV diagnosis decreased of one decade and percentage of female patients was higher. In addition, more patients received diagnosis during hospitalization and more AIDS-defining conditions, such as Pneumocystis pneumonia, were detected. We express our concern that HIV new diagnoses will increase as a result of people's inability to get tested or treated in this period. More efforts are needed to improve local screening programs both during and after COVID-19 pandemic.

18 July 2019 in Infection
Verified
Journal Article
Closed access
GGGiulia Gardini
Giulia Gardini
PZPaola Zanotti
Paola Zanotti
APAlessandro Pucci
Alessandro Pucci
LTLina Tomasoni
Lina Tomasoni
SCSilvio Caligaris
Silvio Caligaris
Francesco CastelliFrancesco Castelli
Francesco Castelli

20 December 2021 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
GGGiulia Gardini
Giulia Gardini
SOSilvia Odolini
Silvia Odolini
GMGiovanni Moioli
Giovanni Moioli
DPDorothea Angela Papalia
Dorothea Angela Papalia
VFVittorio Ferrari
Vittorio Ferrari
SCSilvio Caligaris
Silvio Caligaris
Background: COVID-19 and its related anti-inflammatory treatment (steroids, immunomodulators) may induce the reactivation of latent bacterial, parasitic, and viral infections. According to our knowledge, no case of disseminated HHV-8-related Kaposi sarcoma (KS) after COVID-19 and its treatment has been described so far. Only one case of cutaneous KS concurrently with COVID-19 has been previously reported. Case presentation: We describe a case of disseminated KS in a 61-year-old immunocompetent Albanian man after hospitalization for COVID-19. Methods for literature research: We used PubMed as biomedical database for the literature research. We selected keyword combinations including “Kaposi sarcoma,” “HHV-8,” “immunocompetent,” “COVID-19,” “SARS-CoV-2,” and “steroids.” No time or language limitation was set. Titles and abstracts of selected articles were systematically screened. Articles were included in the examination if they were published under free access through the digital library of the University of Brescia (Italy), and provided full text. Articles were excluded if the topic was beyond the aim of our study. Finally, we selected 15 articles. Results: We describe a case of KS in COVID-19 patient and postulate that Interleukin-6 (IL-6) activity and steroid-induced immunodeficiency may play a major role in KS emergence. No published case of disseminated KS following COVID-19 in otherwise healthy individuals was found through the systematic literature review, despite the high incidence of COVID-19 in areas with medium–high prevalence of HHV-8 infection. This observation might be explained by the role of individual genetic susceptibility factors. Conclusions: SARS-CoV-2 infection and its treatment may lead to reactivation of several latent infections, including HHV-8 and its related clinical syndrome, Kaposi sarcoma.

1 November 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
GGGiulia Gardini
Giulia Gardini
MOMargherita Ori
Margherita Ori
LCLuigi Codecasa
Luigi Codecasa
Alberto Matteelli MatteelliAlberto Matteelli Matteelli
Alberto Matteelli Matteelli